Skyhawk Therapeutics

RNA-correcting Small Molecules

16 additional undisclosed programs RD/Clin0 autoimmune conditions, oncology, muscular & neuromuscular conditions, neurodegenerative conditions

Skyhawk Therapeutics is developing small molecules that modify RNA expression to revolutionize disease treatment. Many diseases are underpinned by changes in RNA expression - Skyhawk is using their unique platform to accelerate the creation of RNA targeting small molecules across a range of fields including neurology, oncology and autoimmune diseases. Skyhawk’s lead program, SKY-0515, is a novel RNA-targeting small molecule that is in clinical trials for Huntington’s disease. SKY-0515 works by reducing the levels of the disease-causing mRNA encoding huntingtin and has shown positive results in a Phase 1 study.